Fig. 5: DAB2IP regulates NLGN3 transcription through Wnt/β-catenin signaling pathway.

A Scheme of DAB2IP functional domains. B Cells were transfected with various functional domains of DAB2IP and NLGN3 mRNA expressions were determined. Means ± SD; One-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001. C Cells were transfected with various functional domains of DAB2IP, and cultured in ultra-low attachment plate under sphere forming condition. Sphere forming ability was calculated based on seeding cell numbers. Means ± SD; One-way ANOVA, ***p < 0.001. D Cells were treated with Wnt/β-catenin inhibitor (LGK974), and NLGN3 protein expressions were compared. E DAB2IP-low cells (A172 KD, U87MG Vc, and LN229 Vc) were treated with LGK974 and NLGN3 mRNA expression was compared. Means ± SD; One-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001. F DAB2IP modulated cells were transfected with NLGN3 promoter containing luciferase and reporter activity was compared by dual luciferase assay. Means ± SD; One-way ANOVA, **p < 0.01. G DAB2IP-low cells transfected with NLGN3 promoter were treated with LGK974 and reporter activity was determined by dual luciferase assay. Means ± SD; One-way ANOVA, **p < 0.01. H DAB2IP-high cells transfected with NLGN3 promoter were treated with Wnt/β-catenin agonist, LiCl and reporter activity was determined by dual luciferase assay. Means ± SD; One-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001.